tirzepatide 20mg vial Research Peptide Tirzepatide, Dual GLP-1 and GIP

Phase Maintenance Weeks 25+ Tirzepatide 15.0 mg/week Cagrilintide 2.4 mg/week Notes Full 3-receptor coverage if tolerated

Your prescriber can extend the titration period at any level if side effects warrant it

This cardioprotective effect makes GLP-1 treatment particularly valuable for patients with multiple health concerns beyond weight management

Commonly experienced side effects can include menstrual irregularities in women, hypoglycemia (low blood sugar), autoimmune-like reactions such as itching or hives, and increased levels of lipase and amylase in the blood

This material is not a drug, supplement, cosmetic, or food, and is not for human or veterinary use, injection, or ingestion

Individuals with compromised immune systems, those on long-term antibiotics, or those consuming high-sugar diets are particularly susceptible